# colorectal cancer - gemini-3.6-flash

- Benchmark system: E2seq + Agent RAG
- Repeat: 3
- Task type: PROGNOSIS
- Tissue / sample source: colorectal tumor tissue
- Comparison or endpoint: overall survival (OS)
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: enabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: Google Gemini / gemini-3.6-flash
- Message SHA-256: dfb8fe82357dbea353d34030380d74028b528c91505f5793c7261ee9e4376675
- Response HTTP status: 200
- Prompt tokens: 82361
- Completion tokens: 75854
- Reasoning tokens: 31488
- Total tokens: 158215
- API requests reported: 5
- Elapsed seconds: 48.928
- RAG status: reused_or_ready
- RAG records/genes reported: 100
- RAG elapsed seconds: 1848.064
- Question handoff seconds: 1861.273
- Final benchmark system: E2seq; file rank 3/5; original repeat 3; model vendor: Google Gemini

---
### 1. Overall Biological Interpretation

The provided transcriptomic dataset consists of 100 unique genes (54 risk-associated with HR > 1; 46 protective-associated with HR < 1) evaluated for association with overall survival (OS) in colorectal cancer (CRC) tumor tissue.

Rather than representing isolated gene changes, the overall profile reveals a functional spectrum characterized by two opposing biological axes:

1. **Risk-Associated Axis (HR > 1; Worse Overall Survival):** High hazard ratios are enriched for genes involved in **TGF-β signaling**, **epithelial-to-mesenchymal transition (EMT)**, **stromal extracellular matrix (ECM) remodeling**, **immunosuppressive purine/adenosinergic signaling**, and **oncogenic receptor signaling**. Key driving transcripts include *INHBB* ($\text{HR}=1.433$, $\text{FDR}=0.00109$), *DCBLD2* ($\text{HR}=1.408$, $\text{FDR}=0.00865$), *ZEB1-AS1* ($\text{HR}=1.372$, $\text{FDR}=0.00865$), *TPM4* ($\text{HR}=1.364$, $\text{FDR}=0.00891$), *NT5E* / CD73 ($\text{HR}=1.313$, $\text{FDR}=0.03939$), *ITGBL1* ($\text{HR}=1.299$, $\text{FDR}=0.03061$), and *FGF19* ($\text{HR}=1.291$, $\text{FDR}=0.05123$). Collectively, these upregulated risk factors reflect a pro-invasive, desmoplastic, and microenvironmentally suppressed tumor state.

2. **Protective-Associated Axis (HR < 1; Favorable Overall Survival):** Low hazard ratios are enriched for transcripts involved in **intestinal epithelial lineage differentiation**, **mitochondrial oxidative phosphorylation (OXPHOS)**, **tricarboxylic acid (TCA) cycle energy metabolism**, and **specialized organic acid/amino acid degradation**. Key protective transcripts include *OGDHL* ($\text{HR}=0.6858$, $\text{FDR}=0.07443$), *ATP23* ($\text{HR}=0.6885$, $\text{FDR}=0.00664$), *NDUFA9* ($\text{HR}=0.6886$, $\text{FDR}=0.00865$), *GLYCTK* ($\text{HR}=0.7093$, $\text{FDR}=0.02034$), *TAPBPL* ($\text{HR}=0.7110$, $\text{FDR}=0.01921$), *CDX2* ($\text{HR}=0.7478$, $\text{FDR}=0.03550$), and *MYO5B* ($\text{HR}=0.7483$, $\text{FDR}=0.02823$). This program highlights that maintenance of enterocyte differentiation identity and mitochondrial oxidative respiration is associated with extended patient survival.

---

### 2. Core Biological Programs

```
                       +-------------------------------------------------------+
                       |              COLORECTAL CANCER OS SPECTRUM            |
                       +-------------------------------------------------------+
                                   /                               \
                                  /                                 \
      RISK PROGRAM (HR > 1; Worse Survival)             PROTECTIVE PROGRAM (HR < 1; Favorable OS)
  +--------------------------------------------+    +--------------------------------------------+
  | - TGF-β / EMT / ECM Remodeling             |    | - Intestinal Epithelial Lineage Identity   |
  |   (INHBB, ZEB1-AS1, ITGBL1, TPM4, DCBLD2)  |    |   (CDX2, CDX1, MYO5B, LGALS4)              |
  | - Immunosuppressive Adenosinergic Axis     |    | - Mitochondrial OXPHOS & TCA Cycle         |
  |   (NT5E/CD73, MSLN, PTPN14)                |    |   (NDUFA9, ATP23, CS, OGDHL, ATP5B)        |
  | - Oncogenic & Cytoskeletal Dynamics        |    | - Primary Amino Acid & Organic Metabolism  |
  |   (AKT3, FGF19, ABL2)                      |    |   (GLYCTK, ASL, MCCC2, PXMP2)              |
  +--------------------------------------------+    +--------------------------------------------+
```

#### Program 1: TGF-β Signaling, Epithelial-Mesenchymal Transition (EMT) & Stromal Remodeling
* **Direction:** Risk-Associated ($\text{HR} > 1$, Poor OS)
* **Major Supporting Genes:** *INHBB* ($\text{HR}=1.433$, $\text{FDR}=0.00109$), *DCBLD2* ($\text{HR}=1.408$, $\text{FDR}=0.00865$), *ZEB1-AS1* ($\text{HR}=1.372$, $\text{FDR}=0.00865$), *TPM4* ($\text{HR}=1.364$, $\text{FDR}=0.00891$), *MIR31HG* ($\text{HR}=1.309$, $\text{FDR}=0.00664$), *ABL2* ($\text{HR}=1.301$, $\text{FDR}=0.02757$), *ITGBL1* ($\text{HR}=1.299$, $\text{FDR}=0.03061$).
* **Standardized Pathway:** Reactome: *TGF-beta receptor signaling activating SMADs* (R-HSA-170838) / GO: *Epithelial to Mesenchymal Transition* (GO:0001837).
* **Biological Explanation:** *INHBB* encodes the Activin $\beta\text{B}$ subunit (a TGF-β superfamily member), while *ZEB1-AS1* and *MIR31HG* are non-coding RNAs that epigenetically stabilize ZEB1 to promote loss of epithelial polarity. *ITGBL1* and *TPM4* modulate focal adhesion integrity and actomyosin stress fiber assembly during cell migration. Together, these genes indicate an active desmoplastic reaction and mesenchymal invasion.
* **Evidence Strength & Limitations:** Strong internal statistical significance (*INHBB*, *ZEB1-AS1*, and *DCBLD2* are top-ranking risk genes with $\text{FDR} < 0.01$). **Limitation:** Bulk RNA profiles cannot separate tumor-cell EMT from cancer-associated fibroblast (CAF) stromal infiltration. *External statistical validation was not performed.*

#### Program 2: Intestinal Epithelial Lineage Differentiation & Mucosal Polarity
* **Direction:** Protective-Associated ($\text{HR} < 1$, Favorable OS)
* **Major Supporting Genes:** *CDX2* ($\text{HR}=0.7478$, $\text{FDR}=0.03550$), *CDX1* ($\text{HR}=0.7809$, $\text{FDR}=0.05735$), *MYO5B* ($\text{HR}=0.7483$, $\text{FDR}=0.02823$), *RAB11FIP4* ($\text{HR}=0.7361$, $\text{FDR}=0.03294$), *LGALS4* ($\text{HR}=0.7712$, $\text{FDR}=0.05123$).
* **Standardized Pathway:** GO: *Cell Differentiation in Intestinal Epithelium* (GO:0030032) / Reactome: *Transcriptional Regulation of Intestinal Epithelial Markers*.
* **Biological Explanation:** *CDX2* and *CDX1* are master caudal-type homeobox transcription factors that enforce intestinal epithelial cell fate and enterocyte differentiation. *MYO5B* and *RAB11FIP4* orchestrate apical membrane polarity and recycling endosome trafficking. Preservation of mature epithelial lineage architecture correlates with lower metastatic potential.
* **Evidence Strength & Limitations:** High biological coherence supported by established GI tumor suppressor literature. **Limitation:** Reduced expression in high-risk tumors may reflect tumor dedifferentiation or low tumor purity relative to expanded stroma. *External statistical validation was not performed.*

#### Program 3: Mitochondrial Oxidative Phosphorylation & TCA Cycle Bioenergetics
* **Direction:** Protective-Associated ($\text{HR} < 1$, Favorable OS)
* **Major Supporting Genes:** *OGDHL* ($\text{HR}=0.6858$, $\text{FDR}=0.07443$), *ATP23* ($\text{HR}=0.6885$, $\text{FDR}=0.00664$), *NDUFA9* ($\text{HR}=0.6886$, $\text{FDR}=0.00865$), *COA3* ($\text{HR}=0.7437$, $\text{FDR}=0.04336$), *ATP5G1* ($\text{HR}=0.7471$, $\text{FDR}=0.05194$), *ATP5B* ($\text{HR}=0.7483$, $\text{FDR}=0.05931$), *TIMM13* ($\text{HR}=0.7509$, $\text{FDR}=0.03938$), *CS* ($\text{HR}=0.7545$, $\text{FDR}=0.03875$).
* **Standardized Pathway:** Reactome: *Respiratory Electron Transport, ATP Synthesis by Chemiosmotic Coupling* (R-HSA-163200) / KEGG: *Citrate cycle (TCA cycle)* (hsa00020).
* **Biological Explanation:** *NDUFA9* (Complex I), *COA3* (Complex IV assembly), *ATP23*, *ATP5B*, and *ATP5G1* (Complex V / $\text{F}_1\text{F}_0$-ATP synthase) form the core electron transport chain, while *CS* (citrate synthase) and *OGDHL* (oxoglutarate dehydrogenase-like) drive the TCA cycle. Uniform protective associations across these 8 genes indicate that intact oxidative mitochondrial respiration correlates with less aggressive tumor behavior.
* **Evidence Strength & Limitations:** Broad multi-gene representation across the respiratory chain with multiple genes at $\text{FDR} < 0.01$. **Limitation:** Does not distinguish metabolic shift from variations in total mitochondrial mass per cell type. *External statistical validation was not performed.*

#### Program 4: Immunosuppressive Adenosinergic Signaling & Microenvironment Modulation
* **Direction:** Risk-Associated ($\text{HR} > 1$, Poor OS)
* **Major Supporting Genes:** *NT5E* / CD73 ($\text{HR}=1.313$, $\text{FDR}=0.03939$), *MSLN* ($\text{HR}=1.313$, $\text{FDR}=0.04507$), *PTPN14* ($\text{HR}=1.362$, $\text{FDR}=0.02501$), *GADD45B* ($\text{HR}=1.324$, $\text{FDR}=0.06300$), *FGF19* ($\text{HR}=1.291$, $\text{FDR}=0.05123$).
* **Standardized Pathway:** KEGG: *Purine metabolism* (hsa0230) / GO: *Regulation Of T Cell Migration* (GO:2000404).
* **Biological Explanation:** *NT5E* encodes CD73, an ecto-5'-nucleotidase that converts extracellular AMP into adenosine, suppressing CD8+ T-cell and NK-cell cytotoxic effector functions. In parallel, *MSLN* and *FGF19* act as cell surface and secretable drivers of tumor cell survival and pro-tumorigenic microenvironmental remodeling.
* **Evidence Strength & Limitations:** Strong biochemical logic for immune evasion; however, RNA expression alone does not measure extracellular adenosine concentration or functional immune exhaustion. *External statistical validation was not performed.*

#### Program 5: Specialized Amino Acid, Organic Acid & Peroxisomal Metabolism
* **Direction:** Protective-Associated ($\text{HR} < 1$, Favorable OS)
* **Major Supporting Genes:** *GLYCTK* ($\text{HR}=0.7093$, $\text{FDR}=0.02034$), *PXMP2* ($\text{HR}=0.7155$, $\text{FDR}=0.02757$), *ILVBL* ($\text{HR}=0.7246$, $\text{FDR}=0.03294$), *CRYM* ($\text{HR}=0.7329$, $\text{FDR}=0.05105$), *ASL* ($\text{HR}=0.7387$, $\text{FDR}=0.03550$), *MCCC2* ($\text{HR}=0.7390$, $\text{FDR}=0.02823$), *ACSS2* ($\text{HR}=0.7577$, $\text{FDR}=0.06021$).
* **Standardized Pathway:** KEGG: *Glycine, serine and threonine metabolism* (hsa00260) / KEGG: *Glyoxylate and dicarboxylate metabolism* (hsa00630).
* **Biological Explanation:** *GLYCTK* (glycerate kinase), *ASL* (argininosuccinate lyase), *MCCC2* (methylcrotonoyl-CoA carboxylase subunit 2), and *PXMP2* (peroxisomal membrane protein 2) govern amino acid catabolism, urea cycle intermediates, and peroxisomal metabolite transport. Loss of these specialized metabolic functions reflects metabolic dedifferentiation.
* **Evidence Strength & Limitations:** Consistently protective hazard ratios across multiple independent metabolic enzymes. **Limitation:** Enzyme activity and intracellular metabolite fluxes were not directly measured. *External statistical validation was not performed.*

---

### 3. Key Genes and Interaction Modules

| Candidate Gene / Module | Direction / Effect Size | Program Membership | Relationship Type | Evidence & Structural Context |
| :--- | :--- | :--- | :--- | :--- |
| **1. INHBB** | Risk ($\text{HR}=1.433$, $\text{P}=2.00\times 10^{-8}$, $\text{FDR}=0.00109$) | TGF-β / EMT Program | **Pathway co-membership & Regulatory interaction** | Top overall risk gene in dataset; ligand upstream of SMAD transcription factors and mesenchymal transition (Europe PMC: 41992239). |
| **2. CDX2** | Protective ($\text{HR}=0.7478$, $\text{P}=2.98\times 10^{-5}$, $\text{FDR}=0.03550$) | Epithelial Lineage Program | **Regulatory interaction** | Master transcription factor enforcing gut enterocyte identity; represses Wnt/$\beta$-catenin tumor signaling (PMID: 30631044). |
| **3. NT5E (CD73)** | Risk ($\text{HR}=1.313$, $\text{P}=4.33\times 10^{-5}$, $\text{FDR}=0.03939$) | Immunosuppressive Program | **Pathway co-membership & Co-expression** | Ecto-enzyme generating extracellular adenosine to inhibit immune infiltration (PMID: 36480312). |
| **4. ATP23 & NDUFA9 Module** | Protective (*ATP23*: $\text{HR}=0.6885$, $\text{FDR}=0.00664$; *NDUFA9*: $\text{HR}=0.6886$, $\text{FDR}=0.00865$) | Mitochondrial OXPHOS Program | **Direct physical interaction & Pathway co-membership** | Outer/inner mitochondrial membrane physical complexes ($F_1F_0$-ATP synthase peptidase chaperone *ATP23* [PMID: 17135288] and Complex I subunit *NDUFA9*). |
| **5. ZEB1-AS1 & MIR31HG** | Risk (*ZEB1-AS1*: $\text{HR}=1.372$, $\text{FDR}=0.00865$; *MIR31HG*: $\text{HR}=1.309$, $\text{FDR}=0.00664$) | TGF-β / EMT Program | **Regulatory interaction & Co-expression** | Non-coding RNA regulators acting epigenetically to promote EMT and invasion networks. |
| **6. ITGBL1 & TPM4** | Risk (*ITGBL1*: $\text{HR}=1.299$, $\text{FDR}=0.03061$; *TPM4*: $\text{HR}=1.364$, $\text{FDR}=0.00891$) | EMT & Remodeling Program | **Co-expression & Pathway co-membership** | Extracellular matrix cross-linking (*ITGBL1*) and actin microfilament stabilization (*TPM4*) regulating focal adhesion dynamics. |
| **7. CS & OGDHL Module** | Protective (*CS*: $\text{HR}=0.7545$, $\text{FDR}=0.03875$; *OGDHL*: $\text{HR}=0.6858$, $\text{FDR}=0.07443$) | TCA Cycle Bioenergetics | **Pathway co-membership** | Key rate-limiting enzymes in the mitochondrial tricarboxylic acid cycle (citrate synthase and $\alpha$-ketoglutarate dehydrogenase). |
| **8. TAPBPL** | Protective ($\text{HR}=0.7110$, $\text{P}=4.92\times 10^{-6}$, $\text{FDR}=0.01921$) | Antigen Processing / Immune Program | **Pathway co-membership & Physical interaction** | TAP-binding protein-like chaperone mediating MHC class I peptide loading and immune presentation. |
| **9. FGF19** | Risk ($\text{HR}=1.291$, $\text{P}=7.87\times 10^{-5}$, $\text{FDR}=0.05123$) | Oncogenic Signaling Program | **Regulatory interaction (Receptor-Ligand)** | Secreted growth factor activating FGFR4 receptor tyrosine kinase autocrine/paracrine growth signaling. |
| **10. ASL & CRYM Module** | Protective (*ASL*: $\text{HR}=0.7387$, $\text{FDR}=0.03550$; *CRYM*: $\text{HR}=0.7329$, $\text{FDR}=0.05105$) | Specialized Amino Acid Program | **Indirect network connection** | Linked via STRING interaction network through arginine/urea cycle metabolic pathways. |

---

### 4. Validation Priorities

#### Priority 1: INHBB / TGF-β Axis as a Prognostic Stromal Remodeling Biomarker
* **Classification:** Biomarker
* **Why Prioritized:** Highest statistical significance and largest hazard ratio among all risk-associated genes ($\text{HR}=1.433$, $\text{P}=2.00\times 10^{-8}$, $\text{FDR}=0.00109$).
* **Input Dataset Evidence:** Strongest univariate risk association in the cohort.
* **External Evidence:** Published literature (Europe PMC: 41992239) confirms *INHBB* upregulation correlates with dismal OS and invasive phenotypes in CRC tissue.
* **Next Step for Validation:** Immunohistochemical (IHC) staining of INHBB protein on independent tissue microarrays (TMAs) from multi-center CRC cohorts, controlling for TNM stage.
* **Status:** **Supported hypothesis** (*external statistical validation was not performed on this dataset*).

#### Priority 2: NT5E (CD73) Immuno-Metabolic Adenosinergic Target
* **Classification:** Therapeutic target
* **Why Prioritized:** Actionable ecto-enzyme regulating extracellular immunosuppressive adenosine production.
* **Input Dataset Evidence:** Significant association with reduced overall survival ($\text{HR}=1.313$, $\text{P}=4.33\times 10^{-5}$, $\text{FDR}=0.03939$).
* **External Evidence:** Published literature (PMID: 36480312) highlights CD73 as a target for cancer immunotherapy and prognostic stratification.
* **Next Step for Validation:** Evaluate anti-CD73 antibody therapy in combination with anti-PD-1 in patient-derived CRC organoid/autologous immune cell co-culture models.
* **Status:** **Supported hypothesis** (*note: target druggability does not guarantee therapeutic efficacy in CRC*).

#### Priority 3: CDX2 / Lineage Preservation Mechanistic Axis
* **Classification:** Mechanistic hypothesis
* **Why Prioritized:** Canonical gut master regulator exhibiting strong protective survival signals ($\text{HR}=0.7478$, $\text{P}=2.98\times 10^{-5}$, $\text{FDR}=0.03550$).
* **Input Dataset Evidence:** Co-directional alignment with intestinal enterocyte lineage markers (*CDX1*, *MYO5B*, *LGALS4*).
* **External Evidence:** Published literature (PMID: 30631044) demonstrates CDX2 directly represses Wnt/$\beta$-catenin signaling by upregulating *GSK3B* and *AXIN2*.
* **Next Step for Validation:** Single-cell RNA sequencing (scRNA-seq) to confirm whether *CDX2* downregulation occurs cell-intrinsically in malignant enterocytes or reflects epithelial-to-stromal ratio shifts.
* **Status:** **Supported hypothesis**.

#### Priority 4: Mitochondrial OXPHOS (ATP23 / NDUFA9) Metabolic Integrity Network
* **Classification:** Interaction / network hypothesis
* **Why Prioritized:** Uniform protective signal across 8 distinct mitochondrial respiratory chain genes (*ATP23*, *NDUFA9*, *CS*, *ATP5B*, *COA3*).
* **Input Dataset Evidence:** *ATP23* ($\text{HR}=0.6885$) and *NDUFA9* ($\text{HR}=0.6886$) are the top protective genes in the dataset.
* **External Evidence:** Functional studies (PMID: 17135288) establish *ATP23* as a critical inner-membrane chaperone required for $F_1F_0$-ATP synthase maturation.
* **Next Step for Validation:** Measure oxygen consumption rate (OCR via Seahorse assay) in CRC cell lines stratified by ATP23/NDUFA9 expression under metabolic stress.
* **Status:** **Exploratory hypothesis**.

#### Priority 5: Cell-Type Composition Confounding Check
* **Classification:** Confounding or composition check
* **Why Prioritized:** High risk HRs (*INHBB*, *ITGBL1*, *TPM4*) may be driven by cancer-associated fibroblast (CAF) abundance, while protective HRs (*CDX2*, *MYO5B*) may reflect high epithelial cell fraction.
* **Input Dataset Evidence:** Bulk tumor sequencing aggregates malignant, stromal, and immune transcripts.
* **External Evidence:** Single-cell CRC atlases indicate strict cell-type compartmentalization of these markers.
* **Next Step for Validation:** Computational deconvolution (e.g., CIBERSORTx) followed by multiplexed immunofluorescence to quantify stromal versus epithelial cell proportions across risk strata.
* **Status:** **Supported hypothesis**.

---

### 5. Evidence Grounding

```
+---------------------------------------------------------------------------------------+
|                                EVIDENCE GROUNDING MATRIX                              |
+-----------------------------------+---------------------------------------------------+
| Evidence Category                 | Applied Input / Context Source                    |
+-----------------------------------+---------------------------------------------------+
| Direct Input Data Evidence        | 100 statistical genes (54 Risk, 46 Protective).   |
| Pathway / Ontology Annotations    | Reactome (TGF-β, OXPHOS), KEGG (TCA, Purine).     |
| Protein Interaction Networks      | STRING database edges (e.g., ATP23-ATP5B; ASL-CRYM).|
| Published Literature Evidence     | PubMed/Europe PMC (e.g., INHBB [41992239],        |
|                                   | CDX2 [30631044], NT5E [36480312]).                |
| External Statistical Validation   | NOT PERFORMED (no external cohort statistics).     |
+-----------------------------------+---------------------------------------------------+
```

* **Direct Evidence:** The uploaded statistical ledger provides primary HR, P-value, and FDR metrics for all 100 selected genes.
* **Pathway & Network Context:** Annotations from Reactome, KEGG, GO, and STRING indicate functional grouping into discrete biological modules (e.g., electron transport chain, EMT). *Note: Network edges and ontology terms represent database annotations, not sample-level statistics.*
* **Published Literature Integration:** Literature records independently support individual candidate roles (e.g., *INHBB* in CRC progression [Europe PMC: 41992239], *CDX2* in Wnt repression [PMID: 30631044], *NT5E* in tumor immunosuppression [PMID: 36480312]).
* **Independence Distinction:** Database annotations (STRING, Reactome, GO) share overlapping literature sources and curation models; they do not represent independent statistical cohorts. *External statistical validation was not performed for this dataset.*

---

### 6. Limitations and Alternative Explanations

1. **Tumor Purity and Cell Composition Confounding:** Bulk tumor tissue transcriptomics blends tumor cells, stromal fibroblasts, endothelial cells, and immune infiltrates. Prominent risk signals (*INHBB*, *ITGBL1*, *TPM4*) may reflect stromal desmoplasia (CAF content) rather than cell-intrinsic aggressiveness of malignant epithelial cells.
2. **Association vs. Causation Ambiguity:** Survival hazard ratios establish prognostic correlation with overall survival, not direct functional causality in driving tumor progression or death.
3. **Unadjusted Clinical Covariates:** The dataset lacks clinical metadata such as TNM stage, microsatellite instability (MSI/MSS) status, anatomical location (left vs. right colon), patient age, and adjuvant chemotherapy exposure (5-FU/oxaliplatin), precluding multivariable Cox proportional hazards adjustment.
4. **Lack of Independent External Cohort Validation:** While literature provides functional context for individual genes, direct statistical validation in an independent patient cohort (e.g., TCGA-COAD or GEO datasets) was not performed.
5. **Probe and Non-Coding Annotation Ambiguity:** The presence of microRNA/lncRNA loci (*ZEB1-AS1*, *MIR31HG*, *LOC101928747|RBMX|SNORD61*) and microarrays probes (*PROBE_237290_at*) introduces hybridization/isoform complexity that requires transcript-specific qPCR or RNA-seq quantification.

This study provides a clear survival profile in colorectal cancer, where activation of TGF-β/EMT stromal remodeling and immunosuppressive adenosine pathways correlates with poor survival, whereas maintenance of CDX2-driven intestinal lineage differentiation and mitochondrial OXPHOS energy metabolism correlates with favorable outcomes.

E2seq statistical audit: selected=100, ledger=100, RAG records=100, numeric claims checked=0, external claims checked=0, external mismatches=0, status=passed.

Answer model API: Google Gemini / gemini-3.6-flash

Source coverage (gene sources = selected items with records / selected RAG items; literature sources = articles / queries)
Online APIs: alliance 86/100 selected items (records returned); cbioportal 78/100 selected items (records returned); chembl 14/100 selected items (partially returned; some queries failed); civic 7/100 selected items (records returned); clinicaltrials 32/100 selected items (records returned); clinvar 83/100 selected items (records returned); ensembl 41/100 selected items (partially returned; some queries failed); europepmc 866 articles / initial full-cohort RAG 100 queries + 4 current-round queries; gtex 81/100 selected items (records returned); gwas 100/100 selected items (records returned); hpa 75/100 selected items (records returned); humanbase 78/100 selected items (records returned); intact 78/100 selected items (records returned); mygene 86/100 selected items (records returned); omnipath 32/100 selected items (records returned); opentargets 40/100 selected items (partially returned; some queries failed); pubmed 699 articles / initial full-cohort RAG 100 queries + 3 current-round queries; quickgo 79/100 selected items (records returned); reactome 100/100 selected items (records returned); uniprot 80/100 selected items (records returned)
Local databases: gutmgene 0/100 selected items (reachable but no records for this batch); hmdb 25/100 selected items (records returned); string 73/100 selected items (records returned); trrust 14/100 selected items (records returned)
